• About
• Links
• Contact
• Sitemap

Sitemap > Breaking Research > Infectious Diseases

• Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261). ACTG 261 Team.
• Hepatitis C virus replication in stably transfected HepG2 cells promotes hepatocellular growth and tumorigenesis.
• The HIV protease inhibitor ritonavir synergizes with butyrate for induction of apoptotic cell death and mediates expression of heme oxygenase-1 in DLD-1 colon carcinoma cells.
• Inhibition of antibiotic efflux in bacteria by the novel multidrug resistance inhibitors biricodar (VX-710) and timcodar (VX-853).
• N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion.
• In vitro combination of amdoxovir and the inosine monophosphate dehydrogenase inhibitors mycophenolic acid and ribavirin demonstrates potent activity against wild-type and drug-resistant variants of human immunodeficiency virus type 1.
• Postentry neutralization of adenovirus type 5 by an antihexon antibody.
• Mucosal delivery of anti-inflammatory IL-1Ra by sporulating recombinant bacteria.
• Studies of nonnucleoside HIV-1 reverse transcriptase inhibitors. Part 1: Design and synthesis of thiazolidenebenzenesulfonamides.
• Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients.
• Human immunodeficiency virus protease inhibitors accumulate into cultured human adipocytes and alter expression of adipocytokines.
• Capravirine, a nonnucleoside reverse-transcriptase inhibitor in patients infected with HIV-1: a phase 1 study.
• Antiviral activity of CYC202 in HIV-1-infected cells.
• Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron.
• Synthesis, physicochemical and pharmacokinetic studies of potential prodrugs of beta-L-2'-deoxycytidine, a selective and specific anti-HBV agent.
• Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1.
• Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.
• Synthesis of N3,5'-cyclo-4-(beta-D-ribofuranosyl)-vic-triazolo[4,5-b]pyridin-5-one, a novel compound with anti-hepatitis C virus activity.
• Tezosentan, an endothelin receptor antagonist, limits liver injury in endotoxin challenged cirrhotic rats.
• Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist.
• Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies.
• Pseudomonas invasion of type I pneumocytes is dependent on the expression and phosphorylation of caveolin-2.
• Cyclooxygenase-2 inhibition improves vascular endothelial dysfunction in a rat model of endotoxic shock: role of inducible nitric-oxide synthase and oxidative stress.
• Pathophysiological role of human beta-defensins 2 in gastric mucosa.
• Mechanistic insights into the suppression of drug resistance by human immunodeficiency virus type 1 reverse transcriptase using alpha-boranophosphate nucleoside analogs.
• Effects of carbon monoxide inhalation during experimental endotoxemia in humans.
• Redirecting the humoral immune response against Streptococcus mutans antigen P1 with monoclonal antibodies.
• Oral vaccination of BALB/c mice with Salmonella enterica serovar Typhimurium expressing Pseudomonas aeruginosa O antigen promotes increased survival in an acute fatal pneumonia model.
• Potent and long-acting dimeric inhibitors of influenza virus neuraminidase are effective at a once-weekly dosing regimen.
• Rapid, simple in vivo screen for new drugs active against Mycobacterium tuberculosis.
• TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.
• Antibacterial activity of a competence-stimulating peptide in experimental sepsis caused by Streptococcus pneumoniae.
• Oral activity of a methylenecyclopropane analog, cyclopropavir, in animal models for cytomegalovirus infections.
• Antistaphylococcal activity of WCK 771, a tricyclic fluoroquinolone, in animal infection models.
• Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells.
• Novel nonnucleoside inhibitor of hepatitis C virus RNA-dependent RNA polymerase.
• Pharmacokinetics in animals and humans of a first-in-class peptide deformylase inhibitor.
• Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells.
• Bystander activity of Ad-mda7: human MDA-7 protein kills melanoma cells via an IL-20 receptor-dependent but STAT3-independent mechanism.
• Antiviral effects of human immunodeficiency virus type 1-specific small interfering RNAs against targets conserved in select neurotropic viral strains.
• Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10.
• Discovery of bicyclic thymidine analogues as selective and high-affinity inhibitors of Mycobacterium tuberculosis thymidine monophosphate kinase.
• Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole.
• Monoclonal antibody hNM01 in HIV-infected patients: a phase I study.
• Therapeutic dendritic-cell vaccine for chronic HIV-1 infection.
• Oncolytic herpes simplex virus mutants are more efficacious than wild-type adenovirus Type 5 for the treatment of high-risk neuroblastomas in preclinical models.
• A pilot study of interleukin-11 in subjects with chronic hepatitis C and advanced liver disease nonresponsive to antiviral therapy.
• Trimeric membrane-anchored gp41 inhibits HIV membrane fusion.
• Artificial cell microcapsule for oral delivery of live bacterial cells for therapy: design, preparation, and in-vitro characterization.
• Serum amyloid A binding to CLA-1 (CD36 and LIMPII analogous-1) mediates serum amyloid A protein-induced activation of ERK1/2 and p38 mitogen-activated protein kinases.
• The effect of hepatitis C on progression to AIDS before and after highly active antiretroviral therapy.
• Infection with concurrent multiple hepatitis C virus genotypes is associated with faster HIV disease progression.
• Animal models for studying respiratory syncytial virus infection and its long term effects on lung function.
• Survival in patients with HIV infection and viral hepatitis B or C: a cohort study.
• The HIV-1 nucleoside reverse transcriptase inhibitors stavudine and zidovudine alter adipocyte functions in vitro.
• The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults.
• Acute renal failure in endotoxemia is dependent on caspase activation.
• Modulators of the human CCR5 receptor. Part 1: Discovery and initial SAR of 1-(3,3-diphenylpropyl)-piperidinyl amides and ureas.
• Anti-coxsackievirus B3 activity of 2-amino-3-nitropyrazolo[1,5-a]pyrimidines and their analogs.
• Design, synthesis and evaluation of 5-substituted amino-2,4-diamino-8-chloropyrimido-[4,5-b]quinolines as novel antimalarials.
• Optimization of pyrrolidinone based HIV protease inhibitors.
• Aminothiazole inhibitors of HCV RNA polymerase.
• Design, synthesis, and structural analysis of inhibitors of influenza neuraminidase containing a 2,3-disubstituted tetrahydrofuran-5-carboxylic acid core.
• Analysis of the neutralizing antibody response elicited in rabbits by repeated inoculation with trimeric HIV-1 envelope glycoproteins.
• The selective cyclooxygenase-2 inhibitor nimesulide prevents Helicobacter pylori-associated gastric cancer development in a mouse model.
• IL-27 signaling compromises control of bacterial growth in mycobacteria-infected mice.
• A novel oral vehicle for poorly soluble HSV-helicase inhibitors: PK/PD validations.
• A systematic approach to the optimization of substrate-based inhibitors of the hepatitis C virus NS3 protease: discovery of potent and specific tripeptide inhibitors.
• Discovery of pyrano[3,4-b]indoles as potent and selective HCV NS5B polymerase inhibitors.
• Identification of novel parasitic cysteine protease inhibitors using virtual screening. 1. The ChemBridge database.
• Endothelin receptor antagonist bosentan improves survival in a murine caecal ligation and puncture model of septic shock.
• Effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on cardiovascular alterations in endotoxemia.
• Respiratory syncytial virus-induced exaggeration of allergic airway disease is dependent upon CCR1-associated immune responses.
• Synchronized infection of cell cultures by magnetically controlled virus.
• Drotrecogin alfa (activated) inhibits NF-kappa B activation and MIP-1-alpha release from isolated mononuclear cells of patients with severe sepsis.
• Activity, safety, and immunological effects of hydroxyurea added to didanosine in antiretroviral-naive and experienced HIV type 1-infected subjects: a randomized, placebo-controlled trial, ACTG 307.
• Orally active CCR5 antagonists as anti-HIV-1 agents. Part 3: Synthesis and biological activities of 1-benzazepine derivatives containing a sulfoxide moiety.
• CCR5 antagonists as anti-HIV-1 agents. Part 3: Synthesis and biological evaluation of piperidine-4-carboxamide derivatives.
• Carbonic anhydrase inhibitors. Inhibition of Plasmodium falciparum carbonic anhydrase with aromatic sulfonamides: towards antimalarials with a novel mechanism of action?
• Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
• Risk of myocardial infarction and stroke after acute infection or vaccination.
• Modelling how ribavirin improves interferon response rates in hepatitis C virus infection.
• Pyrimidine containing RSV fusion inhibitors.
• Recombinant Listeria vaccines containing PEST sequences are potent immune adjuvants for the tumor-associated antigen human papillomavirus-16 E7.
• Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity.
• VFDB: a reference database for bacterial virulence factors.
• Protective role of angiopoietin-1 in endotoxic shock.
• PilX, a pilus-associated protein essential for bacterial aggregation, is a key to pilus-facilitated attachment of Neisseria meningitidis to human cells.
• Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins.
• Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques.
• A novel class of inhibitors of peptide deformylase discovered through high-throughput screening and virtual ligand screening.
• Non-nucleoside benzimidazole-based allosteric inhibitors of the hepatitis C virus NS5B polymerase: inhibition of subgenomic hepatitis C virus RNA replicons in Huh-7 cells.
• Impairment of host resistance to Listeria monocytogenes infection in liver of db/db and ob/ob mice.
• In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant Staphylococcus aureus.
• Antifungal activities of R-135853, a sordarin derivative, in experimental candidiasis in mice.
• Identification of novel inhibitors of bacterial translation elongation factors.
• Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects.
• Single-dose safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, in HIV-infected children.
• The novel parainfluenza virus hemagglutinin-neuraminidase inhibitor BCX 2798 prevents lethal synergism between a paramyxovirus and Streptococcus pneumoniae.
• Accurate multiplex gene synthesis from programmable DNA microchips.
• A mutant of staphylococcal enterotoxin C devoid of bacterial superantigenic activity elicits a Th2 immune response for protection against Staphylococcus aureus infection.
• A peptide mimotope of type 8 pneumococcal capsular polysaccharide induces a protective immune response in mice.
• Eradication of advanced hepatocellular carcinoma in rats via repeated hepatic arterial infusions of recombinant VSV.
• RD114-pseudotyped retroviral vectors kill cancer cells by syncytium formation and enhance the cytotoxic effect of the TK/GCV gene therapy strategy.
• Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene.
• Inhibition of respiratory viruses by nasally administered siRNA.
• CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study.
• Identification and characterization of an endogenous chemotactic ligand specific for FPRL2.
• Efficacy and safety evaluation of human reovirus type 3 in immunocompetent animals: racine and nonhuman primates.
• A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity.
• Lentiviral transduction of microglial cells.
• Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine.
• RNAIII-inhibiting peptide improves efficacy of clinically used antibiotics in a murine model of staphylococcal sepsis.
• Identification of cellular deoxyhypusine synthase as a novel target for antiretroviral therapy.
• IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART.
• Immune and functional role of nitric oxide in a mouse model of respiratory syncytial virus infection.
• In vitro and in vivo anti-leishmanial activity of triterpenoid saponins isolated from Maesa balansae and some chemical derivatives.
• Changes in the novel orphan, C5a receptor (C5L2), during experimental sepsis and sepsis in humans.
• Novel assay using total hepatitis C virus (HCV) core antigen quantification for diagnosis of HCV infection in dialysis patients.
• Parotid secretory protein is an HDL-associated protein with anticandidal activity.
• Neurocognitive changes in patients with hepatitis C receiving interferon alfa-2b and ribavirin.
• Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.
• Clearance of hepatitis B virus from the liver of transgenic mice by short hairpin RNAs.
• Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels.
• New combination test for hepatitis C virus genotype and viral load determination using Amplicor GT HCV MONITOR test v2.0.
• Painful peripheral neuropathy associated with voriconazole use.
• Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium.
• Intracarotid delivery of oncolytic HSV vector G47Delta to metastatic breast cancer in the brain.
• Evaluation of toxicity from high-dose systemic administration of recombinant adenovirus vector in vector-naive and pre-immunized mice.
• Inhibition of endotoxin- and antigen-induced airway inflammation by fudosteine, a mucoactive agent.
• Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.
• Computational design of antiviral RNA interference strategies that resist human immunodeficiency virus escape.
• Anti-CXCR4 monoclonal antibodies recognizing overlapping epitopes differ significantly in their ability to inhibit entry of human immunodeficiency virus type 1.
• Vaccination with an inactivated virulent feline immunodeficiency virus engineered to express high levels of Env.
• Advanced liver fibrosis in HIV/HCV-coinfected patients on antiretroviral therapy.
• Inhibition of HIV type 1 replication using lentiviral-mediated delivery of mutant tRNA(Lys3)A58U.
• Delta24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization.
• Lipodystrophy in patients with HIV-1 infection: effect of stopping protease inhibitors on TNF-alpha and TNF-receptor levels, and on metabolic parameters.
• Antiretroviral drugs with adverse effects on adipocyte lipid metabolism and survival alter the expression and secretion of proinflammatory cytokines and adiponectin in vitro.
• Clevudine therapy with vaccine inhibits progression of chronic hepatitis and delays onset of hepatocellular carcinoma in chronic woodchuck hepatitis virus infection.
• Virological effects of ISIS 14803, an antisense oligonucleotide inhibitor of hepatitis C virus (HCV) internal ribosome entry site (IRES), on HCV IRES in chronic hepatitis C patients and examination of the potential role of primary and secondary HCV resistance in the outcome of treatment.
• Recombinant viral capsids as an efficient vehicle of oligonucleotide delivery into cells.
• Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity.
• HIV-based vectors and angiogenesis following rabbit hindlimb ischemia.
• Enhancement of antiviral activity against hepatitis C virus in vitro by interferon combination therapy.
• Comparative efficacy of acyclovir and vidarabine on the replication of varicella-zoster virus.
• Antileishmanial activity, cytotoxicity and QSAR analysis of synthetic dihydrobenzofuran lignans and related benzofurans.
• CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance.
• RNA polymerase IV directs silencing of endogenous DNA.
• Identification of a peptide derived from vaccinia virus A52R protein that inhibits cytokine secretion in response to TLR-dependent signaling and reduces in vivo bacterial-induced inflammation.
• Engineering the E. coli beta-galactosidase for the screening of antiviral protease inhibitors.
• A randomized, placebo-controlled study of the use of filgrastim in non neutropenic patients with nosocomial pneumonia.
• Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up.
• Adefovir dipivoxil added to ongoing lamivudine therapy in patients with lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B.
• Development and preliminary optimization of indole-N-acetamide inhibitors of hepatitis C virus NS5B polymerase.
• Synthesis of phosphonated carbocyclic 2'-oxa-3'-aza-nucleosides: novel inhibitors of reverse transcriptase.
• Structure-based design, synthesis, and study of potent inhibitors of beta-ketoacyl-acyl carrier protein synthase III as potential antimicrobial agents.
• Identification of small molecule inhibitors of the hepatitis C virus RNA-dependent RNA polymerase from a pyrrolidine combinatorial mixture.
• Synthesis of isonicotinic acid N'-arylidene-N-[2-oxo-2-(4-aryl-piperazin-1-yl)-ethyl]-hydrazides as antituberculosis agents.
• Inhibitors of HCV NS5B polymerase: synthesis and structure-activity relationships of N-1-heteroalkyl-4-hydroxyquinolon-3-yl-benzothiadiazines.
• Design and synthesis of a potent macrocyclic 1,6-naphthyridine anti-human cytomegalovirus (HCMV) inhibitors.
• T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen.
• The cellular HIV-1 Rev cofactor hRIP is required for viral replication.
• Activated protein C inhibits local coagulation after intrapulmonary delivery of endotoxin in humans.
• Lentiviral siRNAs targeting multiple highly conserved RNA sequences of human immunodeficiency virus type 1.
• PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
• Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.
• Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy.
• Response to interferon-based therapies in HIV-infected patients with chronic hepatitis C due to genotype 4.
• Phylloseptins: a novel class of anti-bacterial and anti-protozoan peptides from the Phyllomedusa genus.
• Novel TLR4-antagonizing peptides inhibit LPS-induced release of inflammatory mediators by monocytes.
• Protection against malaria induced by chirally modified Plasmodium falciparum's MSP-1 42 pseudopeptides.
• Engineering of vault nanocapsules with enzymatic and fluorescent properties.
• Synthesis of potent and selective inhibitors of Candida albicans N-myristoyltransferase based on the benzothiazole structure.
• Design, synthesis and evaluation of 2,4-diaminoquinazolines as inhibitors of trypanosomal and leishmanial dihydrofolate reductase.
• Synthesis and inhibitory activity of benzoic acid and pyridine derivatives on influenza neuraminidase.
• Attenuated fever response in mice lacking TRPV1.
• Potent inhibition of HIV-1 entry by (s4dU)35.
• The antimicrobial peptide dermaseptin S4 inhibits HIV-1 infectivity in vitro.
• 1,2,4-Triazino-[5,6b]indole derivatives: effects of the trifluoromethyl group on in vitro antimalarial activity.
• Effects of indomethacin on viral replication markers in asymptomatic carriers of hepatitis B: a randomized, placebo-controlled trial.
• Designer arrays for defined mutant analysis to detect genes essential for survival of Mycobacterium tuberculosis in mouse lungs.
• A1 adenosine receptor knockout mice exhibit increased mortality, renal dysfunction, and hepatic injury in murine septic peritonitis.
• Discovery and characterization of highly immunogenic and broadly recognized mimics of the HIV-1 CTL epitope Gag77-85.
• Prior elevation of IL-18 promotes rapid early IFN-gamma production during staphylococcal infection.
• Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.
• Recognition of bacterial glycosphingolipids by natural killer T cells.
• Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections.
• Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study.
• Antiviral activity of Cidofovir on a naturally human papillomavirus-16 infected squamous cell carcinoma of the head and neck (SCCHN) cell line improves radiation sensitivity.
• Activity of Hoechst 33258 against Pneumocystis carinii f. sp. muris, Candida albicans, and Candida dubliniensis.
• Comparative antimicrobial characterization of LBM415 (NVP PDF-713), a new peptide deformylase inhibitor of clinical importance.
• Comparative safety evaluation of the candidate vaginal microbicide C31G.
• Antifungal activity of flocculosin, a novel glycolipid isolated from Pseudozyma flocculosa.
• Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens.
• SPL7013 gel as a topical microbicide for prevention of vaginal transmission of SHIV89.6P in macaques.
• Druggability indices for protein targets derived from NMR-based screening data.
• High-throughput lipophilicity measurement with immobilized artificial membranes.
• Lipopolysaccharide sequestrants: structural correlates of activity and toxicity in novel acylhomospermines.
• Synthesis of 2',3'-dideoxynucleoside 5'-alpha-P-borano-beta,gamma-(difluoromethylene)triphosphates and their inhibition of HIV-1 reverse transcriptase.
• Excess mortality, length of stay, and costs associated with serious fungal infections among elderly cancer patients: findings from linked SEER-Medicare data.
• Dexamethasone inhibits the HSV-tk/ ganciclovir bystander effect in malignant glioma cells.
• Differential response of TIMP-3 null mice to the lung insults of sepsis, mechanical ventilation, and hyperoxia.
• An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor.
• Effects of non-steroidal anti-inflammatory drugs on the pharmacokinetics and elimination of aciclovir in rats.
• The effect of treatment with a protease inhibitor on mycobacterial infection.
• Potent 1,3,4-trisubstituted pyrrolidine CCR5 receptor antagonists: effects of fused heterocycles on antiviral activity and pharmacokinetic properties.
• Improved synthesis of daunomycin conjugates with triplex-forming oligonucleotides. The polypurine tract of HIV-1 as a target.
• Design, synthesis and anti-plasmodial evaluation in vitro of new 4-aminoquinoline isatin derivatives.
• Neutralization of endotoxin by a phospholipid emulsion in healthy volunteers.
• Vav proteins are required for B-lymphocyte responses to LPS.
• Ipr1 gene mediates innate immunity to tuberculosis.
• Long-term consequences of treatment interruptions in chronically HIV-1-infected patients.
• Oral silymarin for chronic hepatitis C - a retrospective analysis comparing three dose regimens.
• Randomized, investigator-blinded, multicenter study of gatifloxacin versus amoxicillin/clavulanate treatment of recurrent and nonresponsive otitis media in children.
• Compartmentalization of HIV-1 in the central nervous system: role of the choroid plexus.
• Linked tumor-selective virus replication and transgene expression from E3-containing oncolytic adenoviruses.
• An unrelated monoclonal antibody neutralizes human immunodeficiency virus type 1 by binding to an artificial epitope engineered in a functionally neutral region of the viral envelope glycoproteins.
• Cell cycle arrest in G2/M promotes early steps of infection by human immunodeficiency virus.
• Effect of antiviral treatment with entecavir on age- and dose-related outcomes of duck hepatitis B virus infection.
• Mortality risk factors with nosocomial Staphylococcus aureus infections in intensive care units: results from the German Nosocomial Infection Surveillance System (KISS).
• An antibody specific for the C-terminal tail of the gp41 transmembrane protein of human immunodeficiency virus type 1 mediates post-attachment neutralization, probably through inhibition of virus-cell fusion.
• Design, expression, and immunogenicity of a soluble HIV trimeric envelope fragment adopting a prefusion gp41 configuration.
• Toll-like receptor 4 antagonist (E5564) prevents the chronic airway response to inhaled lipopolysaccharide.
• A novel small animal model for HIV-1 infection.
• Suppression of HIV-1 infection by a small molecule inhibitor of the ATM kinase.
• Discovery and optimisation of potent, selective, ethanolamine inhibitors of bacterial phenylalanyl tRNA synthetase.
• Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules.
• The IkappaB kinase is a key factor in triggering influenza A virus-induced inflammatory cytokine production in airway epithelial cells.
• Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection.
• Protection against P. aeruginosa with an adenovirus vector containing an OprF epitope in the capsid.
• Factors associated with the presence of nonalcoholic steatohepatitis in patients with chronic hepatitis C.
• The adipocyte as an important target cell for Trypanosoma cruzi infection.
• Inhibitors of TLR-9 act on multiple cell subsets in mouse and man in vitro and prevent death in vivo from systemic inflammation.
• Peginterferon alpha-2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon alpha-2b plus ribavirin: a pilot study of efficacy and safety.
• Antiviral activity of ovotransferrin derived peptides.
• Outer membrane protein P6 of nontypeable Haemophilus influenzae is a potent and selective inducer of human macrophage proinflammatory cytokines.
• Role of interleukin-6 in mortality from and physiologic response to sepsis.
• Interleukin-15 enhances innate and adaptive immune responses to blood-stage malaria infection in mice.
• Biphenylquinuclidines as inhibitors of squalene synthase and growth of parasitic protozoa.
• Design, synthesis, and biological evaluation of 10-methanesulfonyl-DDACTHF, 10-methanesulfonyl-5-DACTHF, and 10-methylthio-DDACTHF as potent inhibitors of GAR Tfase and the de novo purine biosynthetic pathway.
• Synthesis and biological evaluation of N-[4-[5-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-2-(2,2,2-trifluoroacetyl)pentyl]benzoyl]-L-glutamic acid as a potential inhibitor of GAR Tfase and the de novo purine biosynthetic pathway.
• Aptamers directed to HIV-1 reverse transcriptase display greater efficacy over small hairpin RNAs targeted to viral RNA in blocking HIV-1 replication.
• mda-7/IL24 kills pancreatic cancer cells by inhibition of the Wnt/PI3K signaling pathways: identification of IL-20 receptor-mediated bystander activity against pancreatic cancer.
• Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105.
• The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation.
• Neuroprotective and anti-human immunodeficiency virus activity of minocycline.
• Mixed-lipid storage disorder induced in macrophages and fibroblasts by oritavancin (LY333328), a new glycopeptide antibiotic with exceptional cellular accumulation.
• Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients.
• Immunomodulatory activities of small host defense peptides.
• Phase 1 safety and pharmacokinetic study of chimeric murine-human monoclonal antibody c alpha Stx2 administered intravenously to healthy adult volunteers.
• Clinical pharmacokinetics of alamifovir and its metabolites.
• Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue.
• Targeting Tn5 transposase identifies human immunodeficiency virus type 1 inhibitors.
• Efficacy, plasma pharmacokinetics, and safety of icofungipen, an inhibitor of Candida isoleucyl-tRNA synthetase, in treatment of experimental disseminated candidiasis in persistently neutropenic rabbits.
• Synthesis and antibacterial activity of the 4-quinolone-3-carboxylic acid derivatives having a trifluoromethyl group as a novel N-1 substituent.
• Amino acid 36 in the human immunodeficiency virus type 1 gp41 ectodomain controls fusogenic activity: implications for the molecular mechanism of viral escape from a fusion inhibitor.
• Targeting human glioblastoma cells: comparison of nine viruses with oncolytic potential.
• Functional mimicry of a human immunodeficiency virus type 1 coreceptor by a neutralizing monoclonal antibody.
• Discovery of small-molecule human immunodeficiency virus type 1 entry inhibitors that target the gp120-binding domain of CD4.
• Induction of long-term protective antiviral endogenous immune response by short neutralizing monoclonal antibody treatment.
• New antiviral pathway that mediates hepatitis C virus replicon interferon sensitivity through ADAR1.
• Immunization with the gene expressing woodchuck hepatitis virus nucleocapsid protein fused to cytotoxic-T-lymphocyte-associated antigen 4 leads to enhanced specific immune responses in mice and woodchucks.
• Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates.
• Respiratory syncytial virus infection in elderly and high-risk adults.
• Stage-specific antileishmanial activity of an inhibitor of SIR2 histone deacetylase.
• The successful treatment of gatifloxacin-resistant Staphylococcus aureus keratitis with Zymar (gatifloxacin 0.3%) in a NZW rabbit model.
• Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies.
• 4-Alkyl and 4,4'-dialkyl 1,2-bis(4-chlorophenyl)pyrazolidine-3,5-dione derivatives as new inhibitors of bacterial cell wall biosynthesis.
• Altered adipokine response in murine 3T3-F442A adipocytes treated with protease inhibitors and nucleoside reverse transcriptase inhibitors.
• Biological activity assessment of a novel contraceptive antimicrobial agent.
• Activity and therapeutic potential of ORI-1001 antisense oligonucleotide on human papillomavirus replication utilizing a model of dysplastic human epithelium.
• Biaryl isoxazolinone antibacterial agents.
• Docking simulation with a purine nucleoside specific homology model of deoxycytidine kinase, a target enzyme for anticancer and antiviral therapy.
• Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies.
• Establishment of a screening system for selection of siRNA target sites directed against hepatitis B virus surface gene.
• Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication.
• Design, construction, and characterization of a large synthetic human antibody phage display library.
• Anabolic growth hormone action improves submaximal measures of physical performance in patients with HIV-associated wasting.
• Application of phosphoramidate pronucleotide technology to abacavir leads to a significant enhancement of antiviral potency.
• Design, synthesis, and antipicornavirus activity of 1-[5-(4-arylphenoxy)alkyl]-3-pyridin-4-ylimidazolidin-2-one derivatives.
• Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.
• Mono- and bis-thiazolium salts have potent antimalarial activity.
• A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients.
• KP-1212/1461, a nucleoside designed for the treatment of HIV by viral mutagenesis.
• Identification of a linear peptide recognized by monoclonal antibody 2D7 capable of generating CCR5-specific antibodies with human immunodeficiency virus-neutralizing activity.
• Induction of murine mucosal CCR5-reactive antibodies as an anti-human immunodeficiency virus strategy.
• Varicella-zoster virus ORF4 latency-associated protein is important for establishment of latency.
• HIV protease inhibitors: synthesis and activity of N-aryl-N'-hydroxyalkyl hydrazide pseudopeptides.
• Beta-lactam compounds as apparently uncompetitive inhibitors of HIV-1 protease.
• Evidence that HIV-1 encodes an siRNA and a suppressor of RNA silencing.
• Mycobacterium tuberculosis isocitrate lyases 1 and 2 are jointly required for in vivo growth and virulence.
• Relationship between adherence and the development of resistance in antiretroviral-naive, HIV-1-infected patients receiving lopinavir/ritonavir or nelfinavir.
• In vivo and in vitro studies of a novel cytokine, interleukin 4delta2, in pulmonary tuberculosis.
• Antimicrobial activity and membrane selective interactions of a synthetic lipopeptide MSI-843.
• Proteinase-activated receptor-2 induction by neuroinflammation prevents neuronal death during HIV infection.
• The 4',4'-difluoro analog of 5'-noraristeromycin: a new structural prototype for possible antiviral drug development toward orthopoxvirus and cytomegalovirus.
• Synthesis of new phorbol derivatives having ethereal side chain and evaluation of their anti-HIV activity.
• Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial.
• Antimicrobial activity of murine lung cells against Staphylococcus aureus is increased in vitro and in vivo after elafin gene transfer.
• A novel peptide screened by phage display can mimic TRAP antigen epitope against Staphylococcus aureus infections.
• Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors.
• A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted Regimens (RADAR) study.
• 2H-Pyrrolo[3,4-b] [1,5]benzothiazepine derivatives as potential inhibitors of HIV-1 reverse transcriptase.
• Design, synthesis and biological evaluation of heteroaryl diketohexenoic and diketobutanoic acids as HIV-1 integrase inhibitors endowed with antiretroviral activity.
• Mesuol, a natural occurring 4-phenylcoumarin, inhibits HIV-1 replication by targeting the NF-kappaB pathway.
• Synthesis of glycoporphyrin derivatives and their antiviral activity against herpes simplex virus types 1 and 2.
• Linezolid for the treatment of multidrug-resistant tuberculosis.
• Continuous release of hepatitis C virus (HCV) by peripheral blood mononuclear cells and B-lymphoblastoid cell-line cultures derived from HCV-infected patients.
• Analysis of a 17-amino acid residue, virus-neutralizing microantibody.
• Protein farnesyltransferase inhibitors exhibit potent antimalarial activity.
• Synthesis, antiviral activity, and mechanism of drug resistance of D- and L-2',3'-didehydro-2',3'-dideoxy-2'-fluorocarbocyclic nucleosides.
• Synthesis and antibacterial properties of novel hydrolyzable cationic amphiphiles. Incorporation of multiple head groups leads to impressive antibacterial activity.
• Structure-based design, parallel synthesis, structure-activity relationship, and molecular modeling studies of thiocarbamates, new potent non-nucleoside HIV-1 reverse transcriptase inhibitor isosteres of phenethylthiazolylthiourea derivatives.
• Inhibition of herpes simplex virus thymidine kinases by 2-phenylamino-6-oxopurines and related compounds: structure-activity relationships and antiherpetic activity in vivo.
• Oxytocin protects against sepsis-induced multiple organ damage: role of neutrophils.
• Exploratory analysis for the evaluation of lopinavir/ritonavir-versus efavirenz-based HAART regimens in antiretroviral-naive HIV-positive patients: results from the Italian MASTER Cohort.
• In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease.
• Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis.
• Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models.
• Combination of antimicrobial and endotoxin-neutralizing activities of novel oleoylamines.
• TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates.
• Small molecules VP-14637 and JNJ-2408068 inhibit respiratory syncytial virus fusion by similar mechanisms.
• In vitro and in vivo activities of DA-7867, a new oxazolidinone, against aerobic gram-positive bacteria.
• In vitro activity of doripenem (S-4661) against multidrug-resistant gram-negative bacilli isolated from patients with cystic fibrosis.
• Comparative in vitro activities of investigational peptide deformylase inhibitor NVP LBM-415 and other agents against human mycoplasmas and ureaplasmas.
• The synthetic peptide derived from the NH2-terminal extracellular region of an orphan G protein-coupled receptor, GPR1, preferentially inhibits infection of X4 HIV-1.
• Suppression of virus load by highly active antiretroviral therapy in rhesus macaques infected with a recombinant simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1.
• A virus-encoded inhibitor that blocks RNA interference in mammalian cells.
• A new class of receptor for herpes simplex virus has heptad repeat motifs that are common to membrane fusion proteins.
• Induction of T-cell immunity to antiretroviral drug-resistant human immunodeficiency virus type 1.
• G-protein signaling triggered by R5 human immunodeficiency virus type 1 increases virus replication efficiency in primary T lymphocytes.
• Structural bioinformatics-based design of selective, irreversible kinase inhibitors.
• Cloning, expression, and purification of HIV-2 gp125: A target for HIV vaccination.
• Propranolol ameliorates and epinephrine exacerbates progression of acute and chronic viral myocarditis.
• EBP2 plays a key role in Epstein-Barr virus mitotic segregation and is regulated by aurora family kinases.
• A new approach to an influenza live vaccine: modification of the cleavage site of hemagglutinin.
• Synthesis of substituted indole derivatives as a new class of antimalarial agents.
• Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: The Vacciter Study (ANRS 094).
• Genome-wide requirements for Mycobacterium tuberculosis adaptation and survival in macrophages.
• A monoclonal antibody that inhibits mycobacterial DNA gyrase by a novel mechanism.
• A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
• Hydroxymethylglutaryl co-enzyme A reductase inhibition attenuates endotoxin-mediated inflammatory responses.
• Hypersensitivity of HIV-1-infected cells to reactive sulfonamide metabolites correlated to expression of the HIV-1 viral protein tat.
• Fusogenic liposome delivers encapsulated nanoparticles for cytosolic controlled gene release.
• Inhibition of adenine nucleotide translocator pore function and protection against apoptosis in vivo by an HIV protease inhibitor.
• The human cathelicidin LL-37: a multifunctional peptide involved in infection and inflammation in the lung.
• High-throughput screening of interactions between G protein-coupled receptors and ligands using confocal optics microscopy.
• Anti-HIV activity of (-)-(2R,4R)-1- (2-hydroxymethyl-1,3-dioxolan-4-yl)-thymine against drug-resistant HIV-1 mutants and studies of its molecular mechanism.
• Structure-based characterization and optimization of novel hydrophobic binding interactions in a series of pyrrolidine influenza neuraminidase inhibitors.
• Preparation and characterization of a monoclonal antibody against mannoprotein of Candida albicans.
• A database of recombinant viruses and recombinant viral vectors available from the RIKEN DNA bank.
• Th1-orientated immunological properties of the bacterial extract OM-85-BV.
• Complete replication of hepatitis C virus in cell culture.
• Influenza vaccination is associated with a reduced risk of stroke.
• Leukotriene inhibitors in combination with steroids: potential role in the development of primary bacterial peritonitis.
• Evaluation of AD472, a live attenuated recombinant herpes simplex virus type 2 vaccine in guinea pigs.
• Synthesis of cationic beta-vinyl substituted meso-tetraphenylporphyrins and their in vitro activity against herpes simplex virus type 1.
• Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C.
• Production of infectious hepatitis C virus in tissue culture from a cloned viral genome.
• Small hairpin RNAs efficiently inhibit hepatitis C IRES-mediated gene expression in human tissue culture cells and a mouse model.
• Enhancement of cell mediated immune responses using lipid depleted lentivirus as immunogen: a novel approach for inducing recognition of new viral epitopes.
• Antileishmanial activity of HIV protease inhibitors.
• Interdomain communication in hepatitis C virus polymerase abolished by small molecule inhibitors bound to a novel allosteric site.
• The cysteine-rich region of respiratory syncytial virus attachment protein inhibits innate immunity elicited by the virus and endotoxin.
• Evasion of Toll-like receptor 5 by flagellated bacteria.
• Comparison of qualitative (COBAS AMPLICOR HCV 2.0 versus VERSANT HCV RNA) and quantitative (COBAS AMPLICOR HCV monitor 2.0 versus VERSANT HCV RNA 3.0) assays for hepatitis C virus (HCV) RNA detection and quantification: impact on diagnosis and treatment of HCV infections.
• comparison of two commercial assays for detection of human papillomavirus (HPV) in cervical scrape specimens: validation of the Roche AMPLICOR HPV test as a means to screen for HPV genotypes associated with a higher risk of cervical disorders.
• Human immunodeficiency virus type 1 Vpr impairs dendritic cell maturation and T-cell activation: implications for viral immune escape.
• Novel nuclear export signal-interacting protein, NESI, critical for the assembly of hepatitis delta virus.
• Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteins.
• Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors.
• Growth of respiratory syncytial virus in primary epithelial cells from the human respiratory tract.
• Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia.
• Evaluation of biodistribution and safety of adenovirus vectors containing group B fibers after intravenous injection into baboons.
• Crystal structure of human toll-like receptor 3 (TLR3) ectodomain.
• The Early Systemic Prophylaxis of Infection After Stroke study: a randomized clinical trial.
• Dual effects of extracellular adherence protein from Staphylococcus aureus on peripheral blood mononuclear cells.
• IFN-alpha gene therapy for woodchuck hepatitis with adeno-associated virus: differences in duration of gene expression and antiviral activity using intraportal or intramuscular routes.
• Intrapulmonary and intramyocardial gene transfer in rhesus monkeys (Macaca mulatta): safety and efficiency of HIV-1-derived lentiviral vectors for fetal gene delivery.
• Combined genetic and chemical capsid modifications enable flexible and efficient de- and retargeting of adenovirus vectors.
• Development of a transposon-based approach for identifying novel transgene insertion sites within the replicating adenovirus.
• Inhibition of hepatitis C virus translation and subgenomic replication by siRNAs directed against highly conserved HCV sequence and cellular HCV cofactors.
• Activation of ataxia telangiectasia-mutated DNA damage checkpoint signal transduction elicited by herpes simplex virus infection.
• Cell-based assays to detect inhibitors of fungal mRNA capping enzymes and characterization of sinefungin as a cap methyltransferase inhibitor.
• High-throughput screening with HyperCyt flow cytometry to detect small molecule formylpeptide receptor ligands.
• A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression.
• P2 receptor blockade attenuates fever and cytokine responses induced by lipopolysaccharide in rats.
• Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients.
• Cytotoxic, antiviral (in-vitro and in-vivo), immunomodulatory activity and influence on mitotic divisions of three taxol derivatives: 10-deacetyl-baccatin III, methyl (N-benzoyl-(2'R,3'S)-3'-phenylisoserinate) and N-benzoyl-(2'R,3'S)-3'-phenylisoserine.
• Selection of CMV-specific CD8+ and CD4+ T cells by mini-EBV-transformed B cell lines.
• Antagonizing deactivating cytokines to enhance host defense and chemotherapy in experimental visceral leishmaniasis.
• Intranasal administration of recombinant Neisseria gonorrhoeae transferrin binding proteins A and B conjugated to the cholera toxin B subunit induces systemic and vaginal antibodies in mice.
• Identification of a novel adhesion molecule involved in the virulence of Legionella pneumophila.
• KatA, the major catalase, is critical for osmoprotection and virulence in Pseudomonas aeruginosa PA14.
• Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.
• Abnormal display of PfEMP-1 on erythrocytes carrying haemoglobin C may protect against malaria.
• Transient cutaneous adenoviral gene therapy with human host defense peptide hCAP-18/LL-37 is effective for the treatment of burn wound infections.
• First synthesis and evaluation of the inhibitory effects of aza analogues of TSAO on HIV-1 replication.
• Novel 1-[2-(diarylmethoxy)ethyl]-2-methyl-5-nitroimidazoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. A structure-activity relationship investigation.
• Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1.
• Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease.
• Synthesis and antiviral activities of novel N-alkoxy-arylsulfonamide-based HIV protease inhibitors.
• Oral delivery and gastrointestinal absorption of soluble glucans stimulate increased resistance to infectious challenge.
• HIV protease inhibitors activate the unfolded protein response in macrophages: implication for atherosclerosis and cardiovascular disease.
• Immunomodulatory intervention in sepsis by multidrug-resistant Pseudomonas aeruginosa with thalidomide: an experimental study.
• Synthesis of some diguanidino 1-methyl-2,5-diaryl-1H-pyrroles as antifungal agents.
• Histatin and lactoferrin derived peptides: antimicrobial properties and effects on mammalian cells.
• Gut mucosal T cell responses and gene expression correlate with protection against disease in long-term HIV-1-infected nonprogressors.
• Pharmacology and pharmacokinetics of the antiviral agent beta-D-2',3'-dideoxy-3'-oxa-5-fluorocytidine in cells and rhesus monkeys.
• Antiviral effect of oral administration of tenofovir disoproxil fumarate in woodchucks with chronic woodchuck hepatitis virus infection.
• Drug-induced regulation of the MDR1 promoter in Candida albicans.
• Pharmacokinetics and short-term safety of 873140, a novel CCR5 antagonist, in healthy adult subjects.
• Imipenem for treatment of tuberculosis in mice and humans.
• Safety, pharmacokinetics, and efficacy of (+/-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine with efavirenz and stavudine in antiretroviral-naïve human immunodeficiency virus-infected patients.
• Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy.
• Phage P68 virion-associated protein 17 displays activity against clinical isolates of Staphylococcus aureus.
• In vitro synergy of ciprofloxacin and gatifloxacin against ciprofloxacin-resistant Pseudomonas aeruginosa.
• Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors.
• In vitro and in vivo bactericidal activities of vancomycin dispersed in porous biodegradable poly(epsilon-caprolactone) microparticles.
• In vitro activity of an oral streptogramin antimicrobial, XRP2868, against gram-positive bacteria.
• In vitro antibacterial activity of DX-619, a novel des-fluoro(6) quinolone.
• Modeling long-term HIV dynamics and antiretroviral response: effects of drug potency, pharmacokinetics, adherence, and drug resistance.
• Antibiotics GE23077, novel inhibitors of bacterial RNA polymerase. II. Structure elucidation.
• Investigation of glycine alpha-ketoamide HCV NS3 protease inhibitors: effect of carboxylic acid isosteres.
• Effect of IL-2 on hepatitis C virus RNA levels in patients co-infected with human immunodeficiency virus receiving HAART.
• Intrahepatic gene expression profiles and alpha-smooth muscle actin patterns in hepatitis C virus induced fibrosis.
• Interaction of silver nanoparticles with HIV-1.
• Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.
• Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
• Harmful and protective roles of neutrophils in sepsis.
• Rapid alterations in transferrin sialylation during sepsis.
• Nuclear localization of HIV type 1 Vif isolated from a long-term asymptomatic individual and potential role in virus attenuation.
• Antibiotics GE23077, novel inhibitors of bacterial RNA polymerase. Part 3: Chemical derivatization.
• Novel P1 chain-extended HIV protease inhibitors possessing potent anti-HIV activity and remarkable inverse antiviral resistance profiles.
• Synthesis and antibacterial activity of alkyl derivatives of the glycopeptide antibiotic A40926 and their amides.
• Novel 3-amino-2-hydroxy acids containing protease inhibitors. Part 1: Synthesis and kinetic characterization as aminopeptidase P inhibitors.
• Structure-based design, synthesis, and in vitro assay of novel nucleoside analog inhibitors against HIV-1 reverse transcriptase.
• Antiviral cyclic D,L-alpha-peptides: targeting a general biochemical pathway in virus infections.
• 9-Oxime-3-ketolides: modification at the C-11,12-diol moiety and antibacterial activities against key respiratory pathogens.
• Focal adhesion kinase plays a pivotal role in herpes simplex virus entry.
• Identification of a universal Group B streptococcus vaccine by multiple genome screen.
• Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo.
• Activation of the N-Ras-PI3K-Akt-mTOR pathway by hepatitis C virus: control of cell survival and viral replication.
• Influenza virus infection increases p53 activity: role of p53 in cell death and viral replication.
• A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates.
• Changes in human immunodeficiency virus type 1 fitness and genetic diversity during disease progression.
• Herpes simplex virus type 1 latency-associated transcript expression protects trigeminal ganglion neurons from apoptosis.
• Regulation of human immunodeficiency virus type 1 gene expression by clade-specific Tat proteins.
• In vitro suppression of human immunodeficiency virus type 1 replication by measles virus.
• A genetically engineered attenuated coxsackievirus B3 strain protects mice against lethal infection.
• Antithrombin ameliorates endotoxin-induced organ dysfunction more efficiently when combined with danaparoid sodium than with unfractionated heparin.
• Urokinase-type plasminogen activator, an endogenous antibiotic.
• Synthesis of 6-(3,5-dichlorobenzyl) derivatives as isosteric analogues of the HIV drug 6-(3,5-dimethylbenzyl)-1-(ethoxymethyl)-5-isopropyluracil (GCA-186).
• Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4.
• Synthesis and biological evaluation of geminal disulfones as HIV-1 integrase inhibitors.
• Potent inhibitors of subgenomic hepatitis C virus RNA replication through optimization of indole-N-acetamide allosteric inhibitors of the viral NS5B polymerase.
• Synthesis and biological evaluation of acyclic 3-[(2-hydroxyethoxy)methyl] analogues of antiviral furo- and pyrrolo[2,3-d]pyrimidine nucleosides.
• Attenuated pathogenesis of polymicrobial peritonitis in mice after TLR2 agonist pre-treatment involves ST2 up-regulation.
• In vivo ligation of glucocorticoid-induced TNF receptor enhances the T-cell immunity to herpes simplex virus type 1.
• Angiotensin-converting enzyme 2 protects from severe acute lung failure.
• New alpha-methylene-gamma-butyrolactones with antimycobacterial properties.
• New HIV-1 replication inhibitors of the styryquinoline class bearing aroyl/acyl groups at the C-7 position: synthesis and biological activity.
• Synthesis and antiamoebic activity of new oxime ether derivatives containing 2-acetylpyridine/2-acetylfuran.
• Inhibition of hepatitis B virus gene expression and replication by helioxanthin and its derivative.
• Identification of heteroarylenamines as a new class of antituberculosis lead molecules.
• O-Methylglucogalloyl esters: synthesis and evaluation of their antimycotic activity.
• Isarfelin, a peptide with antifungal and insecticidal activities from Isaria felina.
• Angiopoietin-1 increases arteriolar vasoconstriction to phenylephrine during sepsis.
• HIV-1 Viral protein-r (Vpr) protects against lethal superantigen challenge while maintaining homeostatic T cell levels in vivo.
• A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury.
• HIF-1alpha expression regulates the bactericidal capacity of phagocytes.
• HIV-1 fusion peptide targets the TCR and inhibits antigen-specific T cell activation.
• Effects of the terminal charges in human neutrophil alpha-defensin 2 on its bactericidal and membrane activity.
• Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas.
• Effect of ondansetron, a 5-HT3 receptor antagonist, on fatigue in chronic hepatitis C: a randomised, double blind, placebo controlled study.
• Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/hepatitis C virus-coinfected patients.
• Curcumin has a palliative action on gentamicin-induced nephrotoxicity in rats.
• The beta2 integrin CD11c distinguishes a subset of cytotoxic pulmonary T cells with potent antiviral effects in vitro and in vivo.
• Protection mediated by antibodies to iron-regulated outer-membrane proteins of S. typhi in a mouse peritonitis model.
• An envelope-determined, pH-independent endocytic route of viral entry determines the susceptibility of human immunodeficiency virus type 1 (HIV-1) and HIV-2 to Lv2 restriction.
• Expression of interleukin-4 by recombinant respiratory syncytial virus is associated with accelerated inflammation and a nonfunctional cytotoxic T-lymphocyte response following primary infection but not following challenge with wild-type virus.
• CD4+ T-cell reconstitution reduces cytomegalovirus in the immunocompromised brain.
• Gene expression and antiviral activity of alpha/beta interferons and interleukin-29 in virus-infected human myeloid dendritic cells.
• The promiscuous CC chemokine receptor D6 is a functional coreceptor for primary isolates of human immunodeficiency virus type 1 (HIV-1) and HIV-2 on astrocytes.
• Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus.
• Hepatitis C virus stimulates the expression of cyclooxygenase-2 via oxidative stress: role of prostaglandin E2 in RNA replication.
• Deletion of the herpes simplex virus VP22-encoding gene (UL49) alters the expression, localization, and virion incorporation of ICP0.
• Human immunodeficiency virus reactivation by phorbol esters or T-cell receptor ligation requires both PKCalpha and PKCtheta.
• Age-dependent role for CCR5 in antiviral host defense against herpes simplex virus type 2.
• Genome-wide RNAi screen for host factors required for intracellular bacterial infection.
• Drosophila RNAi screen reveals CD36 family member required for mycobacterial infection.
• The genome sequence of Trypanosoma cruzi, etiologic agent of Chagas disease.
• The genome of the African trypanosome Trypanosoma brucei.
• The Trypanosoma cruzi proteome.
• Inhibition of Hepatitis B virus gene expression by single and dual small interfering RNA treatment.
• Comparative immunogenicity in rhesus monkeys of multi-protein HIV-1 (CRF02_AG) DNA/MVA vaccines expressing mature and immature VLPs.
• Performance of the Roche AMPLICOR human papillomavirus (HPV) test in prediction of cervical intraepithelial neoplasia (CIN) in women with abnormal PAP smear.
• High throughput screening assay for negative single stranded RNA virus polymerase inhibitors.
• The anti-HIV-1 effect of scutellarin.
• Discontinuation of primary prophylaxis against Mycobacterium avium complex infection in HIV-infected persons receiving antiretroviral therapy: observations from a large national cohort in the United States, 1992-2002.
• Inhalative vaccination with pneumococcal polysaccharide in healthy volunteers.
• The global status of resistance to antiretroviral drugs.
• The World Health Organization/International Union Against Tuberculosis and Lung Disease Global Project on Surveillance for Anti-Tuberculosis Drug Resistance: a model for other infectious diseases.
• Inhibition of protein kinases C prevents murine cytomegalovirus replication.
• Interferon-induced exonuclease ISG20 exhibits an antiviral activity against human immunodeficiency virus type 1.
• Opposing effects of CXCR3 and CCR5 deficiency on CD8+ T cell-mediated inflammation in the central nervous system of virus-infected mice.
• CD43 is required for optimal growth inhibition of Mycobacterium tuberculosis in macrophages and in mice.
• The enhancement or prevention of airway hyperresponsiveness during reinfection with respiratory syncytial virus is critically dependent on the age at first infection and IL-13 production.
• Antifungal interventions for the primary prevention of cryptococcal disease in adults with HIV.
• Ribavirin plus interferon versus interferon for chronic hepatitis C.
• A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients.
• Virus-like particle vaccine conferred complete protection against a lethal influenza virus challenge.
• Antagonism of HSV-tk transfection and ganciclovir treatment on chemotherapeutic drug sensitivity.
• Synthesis and assay of isoquinoline derivatives as HIV-1 Tat-TAR interaction inhibitors.
• Synthesis and antimycobacterial evaluation of various 7-substituted ciprofloxacin derivatives.
• Synthesis of novel substituted 2-phenylpyrazolopyridines with potent activity against herpesviruses.
• Oral immunization with a shiga toxin B subunit: rotavirus NSP4(90) fusion protein protects mice against gastroenteritis.
• Streptococcus pyogenes collagen type I-binding Cpa surface protein. Expression profile, binding characteristics, biological functions, and potential clinical impact.
• Human {beta}-defensin 2 is expressed and associated with Mycobacterium tuberculosis during infection of human alveolar epithelial cells.
• Bacterial ghosts as an oral vaccine: a single dose of Escherichia coli O157:H7 bacterial ghosts protects mice against lethal challenge.
• Killed but metabolically active microbes: a new vaccine paradigm for eliciting effector T-cell responses and protective immunity.
• Role of heme oxygenase-1 in endotoxemic acute renal failure.
• Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia.
• Peptide nucleic acid antisense oligomer as a therapeutic strategy against bacterial infection: proof of principle using mouse intraperitoneal infection.
• Lipophilic antifolate trimetrexate is a potent inhibitor of Trypanosoma cruzi: prospect for chemotherapy of Chagas' disease.
• In vitro and in vivo antibacterial activities of CS-023 (RO4908463), a novel parenteral carbapenem.
• Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients.
• Anti-human immunodeficiency virus type 1 activity and resistance profile of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine in vitro.
• Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy.
• Triazine Inhibits Toxoplasma gondii tachyzoites in vitro and in vivo.
• Bactericidal and morphological effects of NE-2001, a novel synthetic agent directed against Helicobacter pylori.
• Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist.
• TAK-220, a novel small-molecule CCR5 antagonist, has favorable anti-human immunodeficiency virus interactions with other antiretrovirals in vitro.
• Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains.
• Therapeutic effect of ME1036 on endocarditis experimentally induced by methicillin-resistant Staphylococcus aureus.
• In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp.
• Identification of an essential molecular contact point on the duck hepatitis B virus reverse transcriptase.
• Generation of an influenza A virus vector expressing biologically active human interleukin-2 from the NS gene segment.
• IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression.
• Therapeutic immunization of highly active antiretroviral therapy-treated HIV-1-infected patients: safety and immunogenicity of an HIV-1 gag/poly-epitope DNA vaccine.
• Ion transport blockers inhibit human rhinovirus 2 release.
• Citridones, new potentiators of antifungal miconazole activity, produced by Penicillium sp. FKI-1938. II. Structure elucidation.
• Caprazamycins, novel lipo-nucleoside antibiotics, from Streptomyces sp. II. Structure elucidation of caprazamycins.
• Priming with plasmid DNAs expressing interleukin-12 and simian immunodeficiency virus gag enhances the immunogenicity and efficacy of an experimental AIDS vaccine based on recombinant vesicular stomatitis virus.
• Transgenic mouse expressing human CCR5 as a model for in vivo assessments of human selective CCR5 antagonists.
• Design and synthesis of depeptidized macrocyclic inhibitors of hepatitis C NS3-4A protease using structure-based drug design.
• A novel immunostimulator, N-[alpha-O-benzyl-N-(acetylmuramyl)-L-alanyl-D-isoglutaminyl]-N6-trans-(m-nitrocinnamoyl)-L-lysine, and its adjuvancy on the hepatitis B surface antigen.
• Antifungal agents. 11. N-substituted derivatives of 1-[(aryl)(4-aryl-1H-pyrrol-3-yl)methyl]-1H-imidazole: synthesis, anti-Candida activity, and QSAR studies.
• A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
• Prime-boost vaccination with plasmid DNA and a chimeric adenovirus type 5 vector with type 35 fiber induces protective immunity against HIV.
• Prevention of recurrent lower urinary tract infections by long-term administration of fosfomycin trometamol. Double blind, randomized, parallel group, placebo controlled study.
• IL-10 from regulatory T cells determines vaccine efficacy in murine Leishmania major infection.
• A soluble factor secreted by an HIV-1-resistant cell line blocks transcription through inactivating the DNA-binding capacity of the NF-kappa B p65/p50 dimer.
• Identification of high and low responders to lipopolysaccharide in normal subjects: an unbiased approach to identify modulators of innate immunity.
• Simultaneous detection of hepatitis C virus (HCV) core antigen and anti-HCV antibodies improves the early detection of HCV infection.
• Design of novel conformational and genotype-specific antigens for improving sensitivity of immunoassays for hepatitis C virus-specific antibodies.
• Evaluation of the ReSSQ assay in relation to the COBAS AMPLICOR CMV MONITOR test and an in-house nested PCR method for detection of cytomegalovirus DNA.
• Treatment of chronic hepatitis C virus infection via antioxidants: results of a phase I clinical trial.
• A phage-displayed cyclic peptide that interacts tightly with the immunodominant region of hepatitis B surface antigen.
• In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061.
• Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants.
• Lamivudine therapy in chronic delta hepatitis: a multicentre randomized-controlled pilot study.
• Domain 5 of high molecular weight kininogen is antibacterial.
• Major depressive episode with psychotic features induced by pegylated interferon-alpha-2b and ribavirin treatment.
• Acetylation of HIV-1 integrase by p300 regulates viral integration.
• Rifampicin+ceftriaxone versus vancomycin+ceftriaxone in the treatment of penicillin- and cephalosporin-resistant pneumococcal meningitis in an experimental rabbit model.
• Beta interferon and gamma interferon synergize to block viral DNA and virion synthesis in herpes simplex virus-infected cells.
• Organ-specific roles for transcription factor NF-kappaB in reovirus-induced apoptosis and disease.
• Bacterial toxins: potential weapons against HIV infection.
• Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein.
• The nonnucleoside reverse transcriptase inhibitor UC-781 inhibits human immunodeficiency virus type 1 infection of human cervical tissue and dissemination by migratory cells.
• Neuronal CXCL10 directs CD8+ T-cell recruitment and control of West Nile virus encephalitis.
• Replication of varicella-zoster virus in human skin organ culture.
• Role of chronic infection and inflammation in the gastrointestinal tract in the etiology and pathogenesis of idiopathic parkinsonism. Part 1: eradication of Helicobacter in the cachexia of idiopathic parkinsonism.
• Role of chronic infection and inflammation in the gastrointestinal tract in the etiology and pathogenesis of idiopathic parkinsonism. Part 2: response of facets of clinical idiopathic parkinsonism to Helicobacter pylori eradication. A randomized, double-blind, placebo-controlled efficacy study.
• Role of chronic infection and inflammation in the gastrointestinal tract in the etiology and pathogenesis of idiopathic parkinsonism. Part 3: predicted probability and gradients of severity of idiopathic parkinsonism based on H. pylori antibody profile.
• A molecular target for suppression of the evolution of antibiotic resistance: inhibition of the Escherichia coli RecA protein by N(6)-(1-naphthyl)-ADP.
• The protein farnesyltransferase inhibitor Tipifarnib as a new lead for the development of drugs against Chagas disease.
• Mapping antimalarial pharmacophores as a useful tool for the rapid discovery of drugs effective in vivo: design, construction, characterization, and pharmacology of metaquine.
• Design, synthesis, and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methylcytidine, a potent inhibitor of hepatitis C virus replication.
• Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites.
• Novel 8-substituted dipyridodiazepinone inhibitors with a broad-spectrum of activity against HIV-1 strains resistant to non-nucleoside reverse transcriptase inhibitors.
• RNA interference is an antiviral defence mechanism in Caenorhabditis elegans.
• Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management.
• Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United Kingdom.
• HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine.
• Suppressor alphabeta T lymphocytes control innate resistance to endotoxic shock.
• Ability of orally administered IFN-alpha-containing transgenic potato extracts to inhibit Listeria monocytogenes infection.
• A novel HBV DNA vaccine based on T cell epitopes and its potential therapeutic effect in HBV transgenic mice.
• Novel sialic acid transporter of Haemophilus influenzae.
• Involvement of fractalkine/CX3CL1 expression by dendritic cells in the enhancement of host immunity against Legionella pneumophila.
• Involvement of toll-like receptor 2 in experimental invasive pulmonary aspergillosis.
• Characterization of MtsR, a new metal regulator in group A streptococcus, involved in iron acquisition and virulence.
• Pulmonary interleukin-23 gene delivery increases local T-cell immunity and controls growth of Mycobacterium tuberculosis in the lungs.
• Cationic liposomes containing mycobacterial lipids: a new powerful Th1 adjuvant system.
• Toward a novel experimental model of infection to study American cutaneous leishmaniasis caused by Leishmania braziliensis.
• Isolation and partial purification of macrophage- and dendritic cell-activating components from Mycoplasma arthritidis: association with organism virulence and involvement with Toll-like receptor 2.
• Therapeutic efficacy of high-dose intravenous immunoglobulin in Mycobacterium tuberculosis infection in mice.
• CpG oligodeoxynucleotides increase the susceptibility of normal mice to infection by Candida albicans.
• In vivo humoral immune responses to isolated pneumococcal polysaccharides are dependent on the presence of associated TLR ligands.
• Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque.
• Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection.
• Phosphatidylinositol 3-kinase is required for rhinovirus-induced airway epithelial cell interleukin-8 expression.
• Defining invasive fungal infections in neutropenic or stem cell transplant patients.
• Pharmacological properties of a new antimalarial bisthiazolium salt, T3, and a corresponding prodrug, TE3.
• Development of a novel targeting system for lethal photosensitization of antibiotic-resistant strains of Staphylococcus aureus.
• Design of a small-molecule entry inhibitor with activity against primary measles virus strains.
• High-throughput human immunodeficiency virus type 1 (HIV-1) full replication assay that includes HIV-1 Vif as an antiviral target.
• Effects of intratracheal administration of novispirin G10 on a rat model of mucoid Pseudomonas aeruginosa lung infection.
• Interleukin-8-derived peptide has antibacterial activity.
• Effect of simvastatin, an established lipid-lowering drug, on pulmonary Chlamydia pneumoniae infection in mice.
• Postantibiotic effect of DX-619 against 16 gram-positive organisms.
• Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice.
• Rab9 GTPase is required for replication of human immunodeficiency virus type 1, filoviruses, and measles virus.
• Deletion of gpUL132, a structural component of human cytomegalovirus, results in impaired virus replication in fibroblasts.
• The Src family kinase c-Yes is required for maturation of West Nile virus particles.
• Molecular footprint of drug-selective pressure in a human immunodeficiency virus transmission chain.
• Molecular basis of replication of duck H5N1 influenza viruses in a mammalian mouse model.
• Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA.
• High-dose interferon-alpha2b induction therapy in combination with ribavirin for treatment of chronic hepatitis C in patients with non-response or relapse after interferon-alpha monotherapy.
• RSV-induced prostaglandin E2 production occurs via cPLA2 activation: role in viral replication.
• Toll-like receptor 3 is induced by and mediates antiviral activity against rhinovirus infection of human bronchial epithelial cells.
• Inactivation of retroviruses with preservation of structural integrity by targeting the hydrophobic domain of the viral envelope.
• Protection of mice against lethal infection with highly pathogenic H7N7 influenza A virus by using a recombinant low-pathogenicity vaccine strain.
• Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells.
• Transfection of Trypanosoma cruzi with host CD40 ligand results in improved control of parasite infection.
• Role of NADase in virulence in experimental invasive group A streptococcal infection.
• Enhancement of innate and cell-mediated immunity by antimycobacterial antibodies.
• Coronaviruses as vectors: stability of foreign gene expression.
• Low TRBP levels support an innate human immunodeficiency virus type 1 resistance in astrocytes by enhancing the PKR antiviral response.
• Oxadiazols: a new class of rationally designed anti-human immunodeficiency virus compounds targeting the nuclear localization signal of the viral matrix protein.
• Inhibitors of respiratory syncytial virus replication target cotranscriptional mRNA guanylylation by viral RNA-dependent RNA polymerase.
• An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge.
• A role for herpesvirus entry mediator as the receptor for herpes simplex virus 1 entry into primary human trabecular meshwork cells.
• Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with human immunodeficiency virus-hepatitis C virus coinfection: results of a randomized clinical study.
• Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired Pneumonia in adults.
• Antiviral activity of GW678248, a novel benzophenone nonnucleoside reverse transcriptase inhibitor.
• Newly designed six-membered azasugar nucleotide-containing phosphorothioate oligonucleotides as potent human immunodeficiency virus type 1 inhibitors.
• Multicenter study to determine antibody concentrations and assess the safety of administration of INH-A21, a donor-selected human Staphylococcal immune globulin, in low-birth-weight infants.
• Evaluation of LBM415 (NVP PDF-713), a novel peptide deformylase inhibitor, for treatment of experimental Mycoplasma pneumoniae pneumonia.
• Efficacy and safety of a novel once-daily extended-release ciprofloxacin tablet formulation for treatment of uncomplicated urinary tract infection in women.
• In vitro and in vivo antibacterial activities of SM-216601, a new broad-spectrum parenteral carbapenem.
• Inhibition of hepatitis C virus replication by antimonial compounds.
• Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin.
• Antibacterial activity of REP8839, a new antibiotic for topical use.
• Inhibition of coreceptor-independent cell-to-cell human immunodeficiency virus type 1 transmission by a CD4-immunoglobulin G2 fusion protein.
• Oral therapy using nanoparticle-encapsulated antituberculosis drugs in guinea pigs infected with Mycobacterium tuberculosis.
• Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus.
• In vitro susceptibility of Mycobacterium tuberculosis clinical isolates to garenoxacin and DA-7867.
• Efficacy of 2-(3,4-dimethyl-2,5-dihydro-1h-pyrrole-2-yl)-1-methylethyl pentanoate in a murine model of invasive aspergillosis.
• Clevudine inhibits hepatitis delta virus viremia: a pilot study of chronically infected woodchucks.
• In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates.
• Dysregulation of bacterial proteolytic machinery by a new class of antibiotics.
• Cellular differentiation-induced attenuation of LPS response in HT-29 cells is related to the down-regulation of TLR4 expression.
• Modeling of activity of cyclic urea HIV-1 protease inhibitors using regularized-artificial neural networks.
• The bacterial HPr kinase/phosphorylase: a new type of Ser/Thr kinase as antimicrobial target.
• In silico fragment-based discovery of indolin-2-one analogues as potent DNA gyrase inhibitors.
• Orally bioavailable highly potent HIV protease inhibitors against PI-resistant virus.
• Anti-tubercular agents. Part 3. Benzothiadiazine as a novel scaffold for anti-Mycobacterium activity.
• Synthesis and biological evaluation of novel lipid A antagonists.
• Persistent NF-kappaB activation in renal epithelial cells in a mouse model of HIV-associated nephropathy.
• Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.
• Molecular mechanisms of autoimmunity triggered by microbial infection.
• CCL5-CCR5 interaction provides antiapoptotic signals for macrophage survival during viral infection.
• Biochemical characterization of recombinant phosphoglucose isomerase of Mycobacterium tuberculosis.
• Synthesis of C-6 substituted pyrazolo[1,5-a]pyridines with potent activity against herpesviruses.
• Synthesis and in vitro anti-hepatitis B and C virus activities of ring-expanded ('fat') nucleobase analogues containing the imidazo[4,5-e][1,3]diazepine-4,8-dione ring system.
• Structure-activity relationships and enzyme inhibition of pantothenamide-type pantothenate kinase inhibitors.
• A QSAR study on influenza neuraminidase inhibitors.
• Polymer-bound 6' sialyl-N-acetyllactosamine protects mice infected by influenza virus.
• 3D-QSAR study of ring-substituted quinoline class of anti-tuberculosis agents.
• The synthesis and biological evaluation of lactose-based sialylmimetics as inhibitors of rotaviral infection.
• Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment.
• Infusion of the beta-adrenergic blocker esmolol attenuates myocardial dysfunction in septic rats.
• Plectasin is a peptide antibiotic with therapeutic potential from a saprophytic fungus.
• Liver-directed gamma interferon gene delivery in chronic hepatitis C.
• Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge.
• Dynamic DNA methylation and histone modifications contribute to lentiviral transgene silencing in murine embryonic carcinoma cells.
• Comparative antigenicity and immunogenicity of hepadnavirus core proteins.
• Combinatorial approach to hepadnavirus-like particle vaccine design.
• Prophylactic alpha interferon treatment increases the therapeutic index of oncolytic vesicular stomatitis virus virotherapy for advanced hepatocellular carcinoma in immune-competent rats.
• LFA-1 is a key determinant for preferential infection of memory CD4+ T cells by human immunodeficiency virus type 1.
• An aptamer that neutralizes R5 strains of human immunodeficiency virus type 1 blocks gp120-CCR5 interaction.
• Synthesis and biological properties of 2-hydroxy-1-(1-phenyltetralyl)piperidine and some of its intermediates as derivatives of phencyclidine.
• Synthesis and evaluation of analgesic/ anti-inflammatory and antimicrobial activities of 3-substituted- 1,2,4-triazole-5-thiones.
• A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients.
• Erythromycin ameliorates renal injury via anti-inflammatory effects in experimental diabetic rats.
• A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40.
• Inhibition of human immunodeficiency virus-1 (HIV-1) by beta-chemokine analogues in mononuclear cells from HIV-1-infected patients with active tuberculosis.
• Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6.
• Solution structure of the human immunodeficiency virus type 1 p6 protein.
• p73 modulates HIV-1 Tat transcriptional and apoptotic activities in human astrocytes.
• Toll-like receptor 2 antagonists. Part 1: preliminary SAR investigation of novel synthetic phospholipids.
• Analogues of N-terminal truncated synthetic peptide fragments derived from RANTES inhibit HIV-1 infectivity.
• 3-Substituted indolizine-1-carbonitrile derivatives as phosphatase inhibitors.
• Identification and characterization of amino acid residues essential for the active site of UDP-N-acetylenolpyruvylglucosamine reductase (MurB) from Staphylococcus aureus.
• Negative regulation of Toll-like-receptor signaling by IRF-4.
• Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults.
• Cutting edge: MyD88 controls phagocyte NADPH oxidase function and killing of gram-negative bacteria.
• CD4 T cell-independent antibody response promotes resolution of primary influenza infection and helps to prevent reinfection.
• Photothermal nanotherapeutics and nanodiagnostics for selective killing of bacteria targeted with gold nanoparticles.
• Immunological control of tuberculosis: role of tumour necrosis factor and more.
• Randomized, placebo-controlled trial of nonpegylated and pegylated forms of recombinant human alpha interferon 2a for suppression of dengue virus viremia in rhesus monkeys.
• Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors.
• Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents.
• High potency of indolyl aryl sulfone nonnucleoside inhibitors towards drug-resistant human immunodeficiency virus type 1 reverse transcriptase mutants is due to selective targeting of different mechanistic forms of the enzyme.
• TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans.
• A class of pantothenic acid analogs inhibits Plasmodium falciparum pantothenate kinase and represses the proliferation of malaria parasites.
• Mouse adenovirus type 1 infection in SCID mice: an experimental model for antiviral therapy of systemic adenovirus infections.
• Analysis of binding sites for the new small-molecule CCR5 antagonist TAK-220 on human CCR5.
• Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.
• Human beta-defensins suppress human immunodeficiency virus infection: potential role in mucosal protection.
• Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor.
• Protective and therapeutic capacity of human single-chain Fv-Fc fusion proteins against West Nile virus.
• In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp.
• Type 1 chemokine receptor expression in Chagas' disease correlates with morbidity in cardiac patients.
• The therapeutic potential of CXCR4 antagonists in the treatment of HIV infection, cancer metastasis and rheumatoid arthritis.
• A protective role for proteinase activated receptor 2 in airways of lipopolysaccharide-treated rats.
• Inhibition of DNA helicases with DNA-competitive inhibitors.
• Cutting edge: murine CD59a modulates antiviral CD4+ T cell activity in a complement-independent manner.
• A novel mucosal vaccine based on live Lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors.
• Crystal structures for HIV-1 reverse transcriptase in complexes with three pyridinone derivatives: a new class of non-nucleoside inhibitors effective against a broad range of drug-resistant strains.
• Design, synthesis, and microbiological evaluation of new Candida albicans CYP51 inhibitors.
• Structure of a synthetic fragment of the lipopolysaccharide (LPS) binding protein when bound to LPS and design of a peptidic LPS inhibitor.
• Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients.
• Synthesis and in vitro antitubercular activity of some 1-[(4-sub)phenyl]-3-(4-{1-[(pyridine-4-carbonyl)hydrazono]ethyl}phenyl)thiourea.
• Inhibition of human immunodeficiency virus type 1 reverse transcriptase, RNase H, and integrase activities by hydroxytropolones.
• Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin.
• Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1.
• Antimalarial activities of new pyrrolo[3,2-f]quinazoline-1,3-diamine derivatives.
• Structure-guided discovery of novel aminoglycoside mimetics as antibacterial translation inhibitors.
• Efficacy of orally administered 2-substituted quinolines in experimental murine cutaneous and visceral leishmaniases.
• High-throughput assays using a luciferase-expressing replicon, virus-like particles, and full-length virus for West Nile virus drug discovery.
• In vitro activity of linezolid against key gram-positive organisms isolated in the united states: results of the LEADER 2004 surveillance program.
• Moxifloxacin and azithromycin but not amoxicillin protect human respiratory epithelial cells against streptococcus pneumoniae in vitro when administered up to 6 hours after challenge.
• A cysteine protease inhibitor protects dogs from cardiac damage during infection by Trypanosoma cruzi.
• Human immunodeficiency virus type 1 latency model for high-throughput screening.
• Respiratory syncytial virus-inducible BCL-3 expression antagonizes the STAT/IRF and NF-kappaB signaling pathways by inducing histone deacetylase 1 recruitment to the interleukin-8 promoter.
• Unique ligand binding sites on CXCR4 probed by a chemical biology approach: implications for the design of selective human immunodeficiency virus type 1 inhibitors.
• Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag.
• Critical role of TRAF3 in the Toll-like receptor-dependent and -independent antiviral response.
• Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6.
• Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, reduces pulmonary inflammatory response in a rat model of endotoxemia.
• CD4+ T cell-independent DNA vaccination against opportunistic infections.
• Carbon monoxide increases macrophage bacterial clearance through Toll-like receptor (TLR)4 expression.
• Synthesis of some novel pyrazolo[3,4-d]pyrimidine derivatives as potential antimicrobial agents.
• A role for LEDGF/p75 in targeting HIV DNA integration.
• Lentiviral vector expression of tumour antigens in dendritic cells as an immunotherapeutic strategy.
• Synthesis and anti-HIV activity of bi-functional betulinic acid derivatives.
• Phosphoramidate and phosphate prodrugs of (-)-beta-D-(2R,4R)-dioxolane-thymine: synthesis, anti-HIV activity and stability studies.
• The vaccine potential of Streptococcus pneumoniae surface lectin- and non-lectin proteins.
• Dengue tetravalent DNA vaccine inducing neutralizing antibody and anamnestic responses to four serotypes in mice.
• The extracellular adherence protein (Eap) of Staphylococcus aureus inhibits wound healing by interfering with host defense and repair mechanisms.
• Vascular endothelial growth factor is increased during the first 48 hours of human septic shock and correlates with vascular permeability.
• The activity of pathway-selective estrogen receptor ligands in experimental septic shock.
• Macrophage migration inhibitory factor within the alveolar spaces induces changes in the heart during late experimental sepsis.
• Ability of the heparan sulfate proteoglycan syndecan-1 to participate in bacterial translocation across the intestinal epithelial barrier.
• Calcitonin gene-related peptide inhibits local acute inflammation and protects mice against lethal endotoxemia.
• Trends in health care resource use for hepatitis C virus infection in the United States.
• Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine.
• Synthesis and anti-HSV-1 activity of quinolonic acyclovir analogues.
• Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease.
• Effect of HIV-1 infection on antimalarial treatment outcomes in Uganda: a population-based study.
• PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial.
• Enhancement of intranasal vaccination in mice with deglycosylated chain A ricin by LTR72, a novel mucosal adjuvant.
• From genome to drug lead: identification of a small-molecule inhibitor of the SARS virus.
• Integration site selection by HIV-based vectors in dividing and growth-arrested IMR-90 lung fibroblasts.
• Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine.
• Hepatitis C virus NS5B delays cell cycle progression by inducing interferon-beta via Toll-like receptor 3 signaling pathway without replicating viral genomes.
• Synthesis and in vitro anti-hepatitis B virus activities of some ethyl 5-hydroxy-1H-indole-3-carboxylates.
• HIV gp41-induced apoptosis is mediated by caspase-3-dependent mitochondrial depolarization, which is inhibited by HIV protease inhibitor nelfinavir.
• Oral delivery of lipid-encapsulated Mycobacterium bovis BCG extends survival of the bacillus in vivo and induces a long-term protective immune response against tuberculosis.
• Adverse events reported following live, cold-adapted, intranasal influenza vaccine.
• Comparison of two human immunodeficiency virus (HIV) RNA surrogate assays to the standard HIV RNA assay.
• The influence of G-CSF addition to antibiotic treatment of experimental sepsis on pulmonary tissue.
• Different stereochemical requirements for CXCR4 binding and signaling functions as revealed by an anti-HIV, D-amino acid-containing SMM-chemokine ligand.
• Use of structure-based drug design approaches to obtain novel anthranilic acid acyl carrier protein synthase inhibitors.
• Diketo acid pharmacophore. 2. Discovery of structurally diverse inhibitors of HIV-1 integrase.
• Antitrypanosomal, antileishmanial, and antimalarial activities of quaternary arylalkylammonium 2-amino-4-chlorophenyl phenyl sulfides, a new class of trypanothione reductase inhibitor, and of N-acyl derivatives of 2-amino-4-chlorophenyl phenyl sulfide.
• A new class of HIV-1 protease inhibitors containing a tertiary alcohol in the transition-state mimicking scaffold.
• Expression profiling of herpesvirus and vaccinia virus proteins using a high-throughput baculovirus screening system.
• A role for heparan sulfate 3-O-sulfotransferase isoform 2 in herpes simplex virus type 1 entry and spread.
• Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine.
• Biological evaluation of isothiazoloquinolones containing aromatic heterocycles at the 7-position: In vitro activity of a series of potent antibacterial agents that are effective against methicillin-resistant Staphylococcus aureus.
• A molecule that is associated with Toll-like receptor 4 and regulates its cell surface expression.
• Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial.
• The viral polymerase mediates adaptation of an avian influenza virus to a mammalian host.